Approval · Notice of Compliance 3553 · 2003
ZOMETA: Notice of Compliance 3553
Issued February 4, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3553
- Date
- February 4, 2003
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: treatment of patients with documented bone metastases from solid tumors and patients with osteolytic lesions of multiple myeloma in conjuction with standard care in order to prevent or delay potential complications from the bone lesions
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZOMETA | Not yet assigned | — |
Medicinal ingredients
- ZOLEDRONIC ACID 4 MG per VIAL